# Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

> **NCT04316351** · PHASE2 · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 60 (estimated)

## Conditions studied

- IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

## Interventions

- **DRUG:** Toripalimab + Pemetrexed + Anlotinib

## Key facts

- **NCT ID:** NCT04316351
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-01
- **Primary completion:** 2022-04-01
- **Final completion:** 2022-04-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04316351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04316351, "Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04316351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*